Financials

  • Market Capitalization 231.68 M
  • Employee 34
  • Founded 2004
  • CEO Christopher U. Missling Ph.D.
  • Website www.anavex.com
  • Headquarter New York, United States
  • FIGI BBG000C9K8K4
  • Industry Biotecnología
Ingresos totales
Beneficio neto
Beneficio básico por acción
Deuda total
Flujo de caja libre
Efectivo y equivalentes
Ratio precio/beneficio
-7.74
Relación precio/flujo de caja
70.17

Related tickers

#NombrePrecio24h %7d %1M %1A %CapitalizaciónÚltimos 7 días
3506
ACIU
AC Immune SA - Common Stock
2.36 USD-2.07%-5.98%0.00%+15.12%240.11 M USD
3516
FULC
Fulcrum Therapeutics, Inc. - Common Stock
3.56 USD-0.84%-4.56%+2.01%-54.71%237.21 M USD
3535
TARA
Protara Therapeutics, Inc. - Common Stock
4.12 USD+0.73%0.00%+7.57%+29.97%231.56 M USD
3553
DTIL
Precision BioSciences, Inc. - Common Stock
8.81 USD+2.68%-3.40%+39.84%+97.98%227.32 M USD

Noticias